Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined - even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.

Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined - even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.